Ablynx Is Granted GLP Certificate for New GLP Unit
Published: Jul 27, 2011
GHENT, BELGIUM--(Marketwire - July 26, 2011) -
GHENT, Belgium, 26 July 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has been granted a Certificate of Good Laboratory Practise (GLP) from the Belgian Scientific Institute of Public Health (IPH) for its new GLP unit at its headquarters in Ghent, Belgium, after having been inspected in May 2011.
Having received this GLP certificate, Ablynx's GLP unit will be able to seamlessly carry out pre-clinical analytical testing and pharmacokinetics studies in-house, to the required regulatory standard.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "Being awarded the GLP certificate from the Belgian authorities confirms our commitment to consistently perform at a high standard in this stringent regulatory environment. This is an important milestone for Ablynx as we continue to grow towards a product- based company. With this certificate, we no longer solely rely on third parties to carry out the pre-clinical GLP testing for our programmes. This enables us to retain more control on quality, timing and associated costs."
About Good Laboratory Practise (GLP)
Good Laboratory Practise specifically refers to a quality system of management controls for research laboratories and organisations to ensure the uniformity, consistency, reliability, reproducibility, quality, and integrity of chemical (including pharmaceuticals) safety and efficacy tests.
Complete version of the press release: http://hugin.info/137912/R/1533547/467177.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact